Sharon Huang

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Induction of Hepatic CYP3A Enzymes by Pregnancy-Related Hormones: Studies in Human Hepatocytes and Hepatic Cell Lines
    Ioannis Papageorgiou
    Department of Pharmaceutics, School of Pharmacy, Box 357610, University of Washington, Seattle, WA 98195 7610
    Drug Metab Dispos 41:281-90. 2013
  2. ncbi A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women
    Alice Ban Ke
    Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    Drug Metab Dispos 41:801-13. 2013
  3. ncbi Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry
    Anand K Deo
    Department of Pharmaceutics, University of Washington, P O Box 357610, Seattle, WA 98195, USA
    Drug Metab Dispos 40:852-5. 2012
  4. ncbi Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion
    Brian J Kirby
    Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, USA
    Drug Metab Dispos 40:610-6. 2012
  5. ncbi Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir
    Brian J Kirby
    Department of Pharmaceutics, University of Washington, Seattle, WA, USA
    Drug Metab Dispos 39:2329-37. 2011
  6. ncbi Placental drug transporters
    Jashvant D Unadkat
    Department of Pharmaceutics, University of Washington, Seattle WA 98195, USA
    Curr Drug Metab 5:125-31. 2004
  7. ncbi Rapid solid-phase extraction method to quantify [(11)C]-verapamil, and its [(11)C]-metabolites, in human and macaque plasma
    Jashvant D Unadkat
    Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    Nucl Med Biol 35:911-7. 2008
  8. ncbi Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women
    Jashvant D Unadkat
    Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    Antimicrob Agents Chemother 51:783-6. 2007
  9. ncbi Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum
    Giovanina M Ellis
    Center for Childhood Infections and Prematurity Research, Seattle Children s Research Institute, Seattle, WA 98101, USA
    J Acquir Immune Defic Syndr 58:241-7. 2011
  10. ncbi Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022
    Jane Hitti
    University of Washington, Seattle, 98195, USA
    J Acquir Immune Defic Syndr 36:772-6. 2004

Research Grants

  1. Nucleoside Transporters: disposition of nucleoside drugs
    Jashvant Unadkat; Fiscal Year: 2007
  2. Mechanisms By Which Maternal And Fetal Drug Exposure Is*
    Jashvant Unadkat; Fiscal Year: 2006
  3. Enhance Effectiveness of Anti-HIV Drugs in the CNS
    Jashvant Unadkat; Fiscal Year: 2003
  4. UPTAKE OF NUCLEOSIDES & NUCLEOSIDE DRUGS IN INTESTINE
    Jashvant Unadkat; Fiscal Year: 2003

Collaborators

  • Mary E Paul
  • D Heather Watts
  • Amin Rostami-Hodjegan
  • Nina Isoherranen
  • Yurong Lai
  • Brian J Kirby
  • Ruth E Tuomala
  • Jashvant Unadkat
  • Jashvant D Unadkat
  • Jane Hitti
  • Ioannis Papageorgiou
  • Alice Ban Ke
  • Anand K Deo
  • Giovanina M Ellis
  • Lisa M Frenkel
  • Ping Zhao
  • Susan Grepper
  • Srikanth C Nallani
  • Larissa Balogh
  • Bhagwat Prasad
  • Dale Whittington
  • Sara Eyal
  • Francisco Chung
  • Jeanne Link
  • David Mankoff
  • Mark Muzi
  • Lucy Sasongko
  • Ann C Collier
  • Paul Deutsch
  • Diane T Holland
  • Elizabeth Smith
  • Bach-Yen Nguyen
  • Bach Yen Nguyen
  • Lynne M Mofenson
  • Kathleen A Kaiser
  • James Connor
  • Diane W Wara
  • Michael D Hughes
  • Anita A Mathias
  • Arthur Provisor
  • Sharon A Nachman
  • David Baker
  • Shashi Vijay
  • Alice M Stek
  • Lee Jen Wei
  • Lee-Jen Wei
  • Laura M Stevens
  • Edwin M Thorpe
  • Amber Dahlin
  • Marc Foca
  • Jorge Gandia
  • Adolfo Gonzalez-Garcia
  • James McNamara

Detail Information

Publications11

  1. ncbi Induction of Hepatic CYP3A Enzymes by Pregnancy-Related Hormones: Studies in Human Hepatocytes and Hepatic Cell Lines
    Ioannis Papageorgiou
    Department of Pharmaceutics, School of Pharmacy, Box 357610, University of Washington, Seattle, WA 98195 7610
    Drug Metab Dispos 41:281-90. 2013
    ....
  2. ncbi A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women
    Alice Ban Ke
    Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    Drug Metab Dispos 41:801-13. 2013
    ..Based on these data, it is prudent to conclude that the magnitude of hepatic CYP2D6 induction during T3 ranges from 100 to 200%. Our PBPK model can predict the disposition of CYP1A2, 2D6, and 3A drugs during pregnancy...
  3. ncbi Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry
    Anand K Deo
    Department of Pharmaceutics, University of Washington, P O Box 357610, Seattle, WA 98195, USA
    Drug Metab Dispos 40:852-5. 2012
    ..In contrast, the single nucleotide polymorphism 21214G>A (V417I; rs2273697) was associated with significantly higher hepatic MRP2 expression...
  4. ncbi Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion
    Brian J Kirby
    Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, USA
    Drug Metab Dispos 40:610-6. 2012
    ..In summary, RTV or NFV do not induce P-glycoprotein activity measured with DIG, and RIF does so only under staggered administration...
  5. ncbi Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir
    Brian J Kirby
    Department of Pharmaceutics, University of Washington, Seattle, WA, USA
    Drug Metab Dispos 39:2329-37. 2011
    ....
  6. ncbi Placental drug transporters
    Jashvant D Unadkat
    Department of Pharmaceutics, University of Washington, Seattle WA 98195, USA
    Curr Drug Metab 5:125-31. 2004
    ..In addition, we will review placental transporters that are important in modulating the exposure of the fetus to drugs and, therefore, the efficacy and toxicity of such drugs towards the fetus...
  7. ncbi Rapid solid-phase extraction method to quantify [(11)C]-verapamil, and its [(11)C]-metabolites, in human and macaque plasma
    Jashvant D Unadkat
    Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    Nucl Med Biol 35:911-7. 2008
    ..Therefore, we developed a rapid solid-phase extraction (SPE) method to separate, and then quantify, verapamil and its radiolabeled metabolites in plasma...
  8. ncbi Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women
    Jashvant D Unadkat
    Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    Antimicrob Agents Chemother 51:783-6. 2007
    ..Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy...
  9. ncbi Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum
    Giovanina M Ellis
    Center for Childhood Infections and Prematurity Research, Seattle Children s Research Institute, Seattle, WA 98101, USA
    J Acquir Immune Defic Syndr 58:241-7. 2011
    ..Compare the risk of HIV drug resistance in women stopping suppressive nelfinavir (NFV)-based or Nevirapine (NVP)-based antiretroviral therapy (ART) after pregnancy...
  10. ncbi Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022
    Jane Hitti
    University of Washington, Seattle, 98195, USA
    J Acquir Immune Defic Syndr 36:772-6. 2004
    ..To compare the safety of nelfinavir and nevirapine-based antiretroviral treatment in HIV-1-infected pregnant women...
  11. ncbi Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir
    Brian J Kirby
    Department of Pharmaceutics, University of Washington, Seattle, WA, USA
    Drug Metab Dispos 39:1070-8. 2011
    ..The magnitude of these DDIs was more accurately predicted using PI CYP3A inactivation parameters generated in sandwich-cultured human hepatocytes rather than human liver microsomes...

Research Grants13

  1. Nucleoside Transporters: disposition of nucleoside drugs
    Jashvant Unadkat; Fiscal Year: 2007
    ..abstract_text> ..
  2. Mechanisms By Which Maternal And Fetal Drug Exposure Is*
    Jashvant Unadkat; Fiscal Year: 2006
    ..Once tested, we will be able to predict the magnitude of change in dose that should be instituted for a wide range of drugs whose disposition is significantly modulated by these transporters. ..
  3. Enhance Effectiveness of Anti-HIV Drugs in the CNS
    Jashvant Unadkat; Fiscal Year: 2003
    ..To test our hypothesis, using PET, that inhibition of P-gp in creases the exposure of CNS to l"1CJ-verapamil and, by inference, protease inhibitors. ..
  4. UPTAKE OF NUCLEOSIDES & NUCLEOSIDE DRUGS IN INTESTINE
    Jashvant Unadkat; Fiscal Year: 2003
    ..abstract_text> ..